
    
      Primary:

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of
      treatment

      Secondary:

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of
      treatment

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of
      treatment

      To evaluate the pharmacokinetics (PK) of MBX-8025

      Exploratory:

      To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and
      renal function

      MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs
    
  